Format

Send to

Choose Destination
Cureus. 2019 Dec 6;11(12):e6312. doi: 10.7759/cureus.6312.

Cannabidiol (CBD) for Treatment of Neurofibromatosis-related Pain and Concomitant Mood Disorder: A Case Report.

Author information

1
Family Medicine, Family Practice, Toronto, CAN.
2
Family Medicine/Chronic Pain and Medical Cannabis, Family Practice, Toronto, CAN.

Abstract

Neurofibromatosis type 1 (NF1) is a common genetic disorder. Pain is a major symptom of this disease which can be secondary to the development of plexiform and subcutaneous neurofibromas, musculoskeletal symptoms (such as scoliosis and pseudoarthrosis), and headaches. Visible neurofibromas add significant psychosocial distress for NF1 patients. Along with the chronic pain, psychosocial distress contributes to associated mood disorders, such as depression and anxiety. Cannabis has been the focus of many studies for treating multiple conditions, including epilepsy, multiple sclerosis, Parkinsonism disease, and many chronic pain conditions. Cannabidiol (CBD) is the major non-psychotropic component of cannabis. CBD has shown anti-inflammatory and analgesic properties, as well as having mood stabilizer and anxiolytic effects. In this report, we present the use of cannabidiol (CBD) for the management of chronic pain and concomitant mood disorder in an NF1 patient.

KEYWORDS:

anxiety; cannabidiol; depression; neurofibromatosis type 1 (nf1); pain

Conflict of interest statement

The authors have declared that no competing interests exist.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center